首页> 美国卫生研究院文献>Antioxidants Redox Signaling >Adeno-sh-β-Catenin Abolishes Ischemic Preconditioning–Mediated Cardioprotection by Downregulation of Its Target Genes VEGF Bcl-2 and Survivin in Ischemic Rat Myocardium
【2h】

Adeno-sh-β-Catenin Abolishes Ischemic Preconditioning–Mediated Cardioprotection by Downregulation of Its Target Genes VEGF Bcl-2 and Survivin in Ischemic Rat Myocardium

机译:腺sh-β-连环蛋白通过下调其在缺血大鼠心肌中的靶基因VEGFBcl-2和survivin的表达来消除缺血预处理介导的心脏保护作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

β-Catenin, the downstream target of glycogen synthase kinase-3β (GSK-3β), plays a vital role in ischemic preconditioning (IP)-mediated cardioprotection. In the present study, we investigated the mechanism of IP-mediated cardioprotection through suppression of β-catenin expression by intramyocardial injection of adeno-sh-RNA against β-catenin (BCT) (4 × 108 pfu). Adeno-LacZ (LZ) was used as control. The rats were randomized into (a) LZ + ischemia–reperfusion (IR); (b) LZIPIR; (c) BCTIR; and (d) BCTIPIR. Isolated hearts from each group were subjected to 30 min of I followed by 2 h of R. Both IPIR group hearts were subjected to IP (5 min I + 10 min R; four cycles) before IR. Significant reduction in left ventricular functional recovery (78 vs. 88 mm Hg), dp/dtmax (1,802 vs. 2,189 mm Hg/sec), and aortic flow (4 vs. 9 ml/min) was observed in BCTIPIR compared with LZIPIR at 120 min of reperfusion. Increased infarct size (42 vs. 24%) and apoptotic cardiomyocytes (122 vs. 58 counts/60 HPF) were observed in BCTIPIR compared with LZIPIR. Real-time PCR and Western blot analysis showed significant downregulation in mRNA and protein expression of VEGF, Bcl-2, and survivin in BCTIPIR compared with LZIPIR. These findings indicated for the first time that silencing β-catenin abolished IP-mediated cardioprotection, probably through inhibition of VEGF-Bcl-2 and survivin. Antioxid. Redox Signal. 10, 1475–1485.
机译:β-catenin是糖原合酶激酶3β(GSK-3β)的下游靶标,在缺血预处理(IP)介导的心脏保护中起着至关重要的作用。在本研究中,我们研究了心肌内注射针对β-catenin(BCT)(4×10 8 pfu的腺sh-RNA抑制β-catenin表达的IP介导的心脏保护机制。 )。腺-LacZ(LZ)用作对照。将大鼠随机分为(a)LZ +缺血再灌注(IR); (b)LZIPIR; (c)BCTIR; (d)BCTIPIR。每组离体的心脏均接受30μmin的I,然后接受2μh的R。IPIR组的两个心脏均接受IR(5μminI + + 10μminR;四个周期)后进行IR。在BCTIPIR与LZIPIR相比,观察到左室功能恢复(78 vs. 88 recoverymm Hg),dp / dtmax(1802 vs. 2189 mm Hg / sec)和主动脉血流量显着降低(4 vs. 9 ml / min)。再灌注120分钟。与LZIPIR相比,BCTIPIR观察到梗死面积增大(42%vs. 24%)和凋亡性心肌细胞(122 vs. 58计数/ 60 HPF)。实时PCR和蛋白质印迹分析显示,与LZIPIR相比,BCTIPIR中VEGF,Bcl-2和survivin的mRNA和蛋白表达显着下调。这些发现首次表明沉默β-连环蛋白可能通过抑制VEGF-Bcl-2和survivin而消除了IP介导的心脏保护作用。抗氧化。氧化还原信号。 10,1475-1485。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号